Three blood markers may flag who develops lung failure after chest injury
NCT ID NCT07774338
First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time
Summary
This study looks at whether three blood markers—sRAGE, CC16, and Syndecan-1—measured soon after a severe chest injury can predict who will develop acute respiratory distress syndrome (ARDS), a serious lung condition, and who might die in the hospital. Adults aged 18 to 60 with severe blunt or penetrating chest trauma will be enrolled, and their blood will be tested early. Researchers will follow them for a week to see if ARDS develops and track outcomes until discharge. The goal is to find simple early clues that help identify high-risk patients sooner.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors quickly identify chest trauma patients at high risk of severe lung injury, enabling earlier and more targeted care.
- What could go wrong
- This is an observational study, so it cannot prove cause and effect. The findings may not apply to all patients, and the biomarkers may not be accurate enough for routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 85 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will include adult patients aged 18 years or older admitted to the trauma unit with severe blunt or penetrating chest trauma. All eligible participants will undergo clinical assessment, routine laboratory and radiological evaluation, and single blood sampling for measurement of serum sRAGE, CC16, and Syndecan-1 levels. Participants will be followed prospectively for the development of ARDS during the first 7 days after admission, while in-hospital mortality will be recorded until hospital discharge or death.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients aged 18 - 60 years old. * Patients with blunt or penetrating severe chest trauma. * Chest Abbreviated Injury Scale (Chest AIS ≥3). * Admission within 24 hours of injury. * Patients admitted to the Trauma Unit or Trauma ICU. * Written informed consent obtained from the patient or legally authorized representative. Exclusion Criteria: * h. Age below 18 years or above 60 years old (to ensure a homogeneous adult study population and avoid age- related physiological differences). * i. Hospital admission more than 24 hours after injury (to ensure early biomarker measurement before secondary inflammatory changes occur). * j. Previous diagnosis of acute respiratory distress syndrome before admission (to ensure that ARDS outcomes are attributable to the index chest trauma). * k. Pre-existing chronic interstitial lung disease (to avoid baseline pulmonary abnormalities that may influence biomarker levels and respiratory outcomes). * l. Acute exacerbation of chronic obstructive pulmonary disease requiring hospitalization (to minimize confounding from pre-existing acute pulmonary inflammation). * m. Active pulmonary infection before trauma (to exclude pre-existing pulmonary inflammation that may alter biomarker levels and increase the risk of ARDS independently of trauma). * n. End-stage chronic liver disease (to avoid altered inflammatory responses and poor clinical outcomes unrelated to chest trauma). * o. End-stage renal disease requiring dialysis (to avoid altered clearance of circulating biomarkers and independently increased mortality risk). * p. Active malignancy receiving chemotherapy or radiotherapy (to exclude patients with cancer-related systemic inflammation and immunosuppression that may affect biomarker levels and outcomes). * q. Pregnancy (because physiological changes during pregnancy may influence biomarker levels and respiratory function). * r. Patients transferred from another hospital more than 24 hours after injury (to ensure standardized early clinical assessment and biomarker sampling within the predefined study period). * s. Refusal to participate in the study (because informed consent is required for study enrollment). * t. Connective tissue diseases * u. Severe burns and major inhalational injury v. Immunosuppressive therapy * w. Chronic systemic inflammatory diseases * x. Severe obesity ( BMI\>40), if relevant. * y. Poly trauma with AIS\> or = 3 outside the chest.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute respiratory distress syndrome are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adjusting breathing effort during ventilation improve lung function in ARDS?
- Which steroid best fights ARDS? a Head-to-Head trial aims to find out
- Can a Radiation-Free scan reveal how ARDS treatments reshape lung blood flow?
- Can a Lung-Opening maneuver change a key injury marker in ARDS?
- Could simply sitting up ease breathing in severe lung failure?
- Could lung fluid proteins reveal a new way to track severe lung injury?